Marinus Pharmaceuticals Debt To Equity Over Time
MRNS Stock | USD 0.33 0.01 3.13% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Marinus Pharmaceuticals Performance and Marinus Pharmaceuticals Correlation. Marinus |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Marinus Pharmaceuticals. If investors know Marinus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Marinus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.47) | Revenue Per Share 0.539 | Quarterly Revenue Growth 0.325 | Return On Assets (0.58) | Return On Equity (29.87) |
The market value of Marinus Pharmaceuticals is measured differently than its book value, which is the value of Marinus that is recorded on the company's balance sheet. Investors also form their own opinion of Marinus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Marinus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Marinus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Marinus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Marinus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Marinus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Marinus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Debt To Equity Analysis
Compare Marinus Pharmaceuticals and related stocks such as Akero Therapeutics, Terns Pharmaceuticals, and Madrigal Pharmaceuticals Debt To Equity Over Time
Select Fundamental2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
AKRO | 0.0059 | 0.0059 | 0.0059 | 0.0059 | 0.0059 | 0.0059 | 0.0059 | 0.0059 | 0.0059 | 0.0059 | 0.0059 | 0.0078 | 0.0292 | 0.0466 | 0.049 |
TERN | 0.1878 | 0.1878 | 0.1878 | 0.1878 | 0.1878 | 0.1878 | 0.1878 | 0.1878 | 0.1878 | 0.1878 | 0.1878 | 0.0024 | 0.0024 | 0.0024 | 0.0022 |
MDGL | 0.0046 | 1.1251 | 0.1652 | 0.4749 | 0.2128 | 0.9641 | 8.0E-4 | 8.0E-4 | 8.0E-4 | 8.0E-4 | 0.0013 | 0.0021 | 0.2497 | 0.2862 | 0.3 |
INZY | 0.0067 | 0.0067 | 0.0067 | 0.0067 | 0.0067 | 0.0067 | 0.0067 | 0.0067 | 0.0067 | 0.0067 | 0.0067 | 0.0067 | 0.0418 | 0.3252 | 0.34 |
VKTX | (0.4055) | (0.4055) | (0.4055) | (1.1123) | (0.0709) | 0.2466 | 0.4065 | 0.2563 | 0.0011 | 0.0011 | 0.0014 | 1.0E-4 | 0.0021 | 9.0E-4 | 0.001 |
ETNB | (0.1041) | (0.1041) | (0.1041) | (0.1041) | (0.1041) | (0.1041) | (0.1041) | (0.1041) | (0.1041) | 0.154 | 0.154 | 0.154 | 0.1308 | 0.0472 | 0.0456 |
CABA | 0.0208 | 0.0208 | 0.0208 | 0.0208 | 0.0208 | 0.0208 | 0.0208 | 0.0208 | 0.0208 | 0.0208 | 0.0208 | 0.0208 | 0.0208 | 0.0151 | 0.0198 |
MIRM | (0.0522) | (0.0522) | (0.0522) | (0.0522) | (0.0522) | (0.0522) | (0.0522) | (0.0522) | (0.0522) | (0.0522) | (0.0188) | 0.0217 | (0.0056) | 1.2367 | 1.3 |
ABOS | 6.0E-4 | 6.0E-4 | 6.0E-4 | 6.0E-4 | 6.0E-4 | 6.0E-4 | 6.0E-4 | 6.0E-4 | 6.0E-4 | 6.0E-4 | 6.0E-4 | 6.0E-4 | 6.0E-4 | 0.1056 | 0.11 |
XFOR | (0.2096) | (0.2096) | (0.2096) | (0.2096) | (0.2096) | (0.2096) | (0.2698) | 0.2084 | 0.4436 | 0.1625 | 0.4665 | 0.5435 | 0.4702 | 1.0894 | 1.14 |
IKNA | (1.3651) | (1.3651) | (1.3651) | (1.3651) | (1.3651) | (1.3651) | (1.3651) | (1.3651) | (1.3651) | (1.2832) | 0.1761 | 0.0089 | 0.013 | 0.021 | 0.022 |
OVID | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
CNTB | (4.5194) | (4.5194) | (4.5194) | (4.5194) | (4.5194) | (4.5194) | (4.5194) | (4.5194) | (4.5194) | (6.0E-4) | (6.0E-4) | (6.0E-4) | (6.0E-4) | (5.0E-4) | (6.0E-4) |
EWTX | 0.0018 | 0.0018 | 0.0018 | 0.0018 | 0.0018 | 0.0018 | 0.0018 | 0.0018 | 0.0018 | 0.0018 | 0.0018 | 0.0018 | 0.0018 | 0.0031 | 0.0019 |
PMVP | 0.0013 | 0.0013 | 0.0013 | 0.0013 | 0.0013 | 0.0013 | 0.0013 | 0.0013 | 0.0013 | 0.0013 | 0.0013 | 0.0013 | 0.0021 | 0.0038 | 0.0019 |
CGEM | 3.0E-4 | 3.0E-4 | 3.0E-4 | 3.0E-4 | 3.0E-4 | 3.0E-4 | 3.0E-4 | 3.0E-4 | 3.0E-4 | 3.0E-4 | 3.0E-4 | 3.0E-4 | 3.0E-4 | 0.0032 | 0.0033 |
ELVN | (0.0425) | (0.0425) | (0.0425) | (0.0425) | (0.0425) | (0.0425) | (0.0425) | (0.0425) | (0.0425) | (0.0425) | (0.0425) | (0.0425) | (0.0425) | (0.0382) | (0.0402) |
IMRX | (2.5451) | (2.5451) | (2.5451) | (2.5451) | (2.5451) | (2.5451) | (2.5451) | (2.5451) | (2.5451) | (2.5451) | (2.5451) | (2.5451) | (2.5451) | (2.29) | (2.41) |
Marinus Pharmaceuticals and related stocks such as Akero Therapeutics, Terns Pharmaceuticals, and Madrigal Pharmaceuticals Debt To Equity description
A measure of a company's financial leverage calculated by dividing its total liabilities by stockholders' equity, indicating the proportion of equity and debt the company is using to finance its assets.My Equities
My Current Equities and Potential Positions
Marinus Pharmaceuticals | MRNS |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Location | Pennsylvania; U.S.A |
Exchange | NASDAQ Exchange |
USD 0.33
Additional Tools for Marinus Stock Analysis
When running Marinus Pharmaceuticals' price analysis, check to measure Marinus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marinus Pharmaceuticals is operating at the current time. Most of Marinus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Marinus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marinus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Marinus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.